Literature DB >> 24387201

Immune deficiency in Ataxia-Telangiectasia: a longitudinal study of 44 patients.

C Chopra1, G Davies, M Taylor, M Anderson, S Bainbridge, P Tighe, E M McDermott.   

Abstract

Ataxia-Telangiectasia (A-T) is a genetic condition leading to neurological defects and immune deficiency. The nature of the immune deficiency is highly variable, and in some cases causes significant morbidity and mortality due to recurrent sinopulmonary infections. Although the neurological defects in A-T are progressive, the natural history of the immune deficiency in A-T has not been evaluated formally. In this study we analyse the clinical history and immunological data in 44 patients with A-T who attended the National Ataxia-Telangiectasia clinic in Nottingham between 2001 and 2011. Using patient medical records and Nottingham University Hospitals (NUH) National Health Service Trust medical IT systems, data regarding clinical history, use of immunoglobulin replacement therapy, total immunoglobulin levels, specific antibody levels and lymphocyte subset counts were obtained. T cell receptor spectratyping results in some patients were already available and, where possible, repeat blood samples were collected for analysis. This study shows that subtle quantitative changes in certain immunological parameters such as lymphocyte subset counts may occur in patients with A-T over time. However, in general, for the majority of patients the severity of immune deficiency (both clinically and in terms of immunological blood markers) does not seem to deteriorate significantly with time. This finding serves to inform the long-term management of this cohort of patients because, if recurrent respiratory tract infections present later in life, then other contributory factors (e.g. cough/swallowing difficulties, underlying lung disease) should be investigated aggressively. Our findings also offer some form of reassurance for parents of children with A-T, which is otherwise a progressively severely debilitating condition.
© 2014 British Society for Immunology.

Entities:  

Keywords:  Ataxia-Telangiectasia; immune deficiency; infection

Mesh:

Substances:

Year:  2014        PMID: 24387201      PMCID: PMC3992040          DOI: 10.1111/cei.12262

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  19 in total

1.  Selective deficiency of CD4+/CD45RA+ lymphocytes in patients with ataxia-telangiectasia.

Authors:  R Paganelli; E Scala; E Scarselli; C Ortolani; A Cossarizza; D Carmini; F Aiuti; M Fiorilli
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

2.  Update on the management of the immunodeficiency in ataxia-telangiectasia.

Authors:  E Graham Davies
Journal:  Expert Rev Clin Immunol       Date:  2009-09       Impact factor: 4.473

3.  Survival probability in ataxia telangiectasia.

Authors:  T O Crawford; R L Skolasky; R Fernandez; K J Rosquist; H M Lederman
Journal:  Arch Dis Child       Date:  2006-07       Impact factor: 3.791

4.  Serum IgD concentrations in patients with ataxia telangiectasia and with selective IgA deficiency.

Authors:  O Sanal; F Ozaltin; I Tezcan; F Ersoy
Journal:  Int Arch Allergy Immunol       Date:  1998-07       Impact factor: 2.749

Review 5.  The ATM protein kinase: regulating the cellular response to genotoxic stress, and more.

Authors:  Yosef Shiloh; Yael Ziv
Journal:  Nat Rev Mol Cell Biol       Date:  2013-03-13       Impact factor: 94.444

6.  Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia.

Authors:  O Sanal; F Ersoy; L Yel; I Tezcan; A Metin; H Ozyürek; S Gariboglu; S Fikrig; A I Berkel; G T Rijkers; B J Zegers
Journal:  J Clin Immunol       Date:  1999-09       Impact factor: 8.317

7.  Premature ageing of the immune system underlies immunodeficiency in ataxia telangiectasia.

Authors:  Andrew Robert Exley; Samantha Buckenham; Elizabeth Hodges; Robert Hallam; Phil Byrd; James Last; Claire Trinder; Susan Harris; Nicholas Screaton; Anthony P Williams; A Malcolm R Taylor; John M Shneerson
Journal:  Clin Immunol       Date:  2011-03-13       Impact factor: 3.969

8.  Intact T cell responses in ataxia telangiectasia.

Authors:  Farzana Pashankar; Vibha Singhal; Ike Akabogu; Richard A Gatti; Frederick D Goldman
Journal:  Clin Immunol       Date:  2006-06-08       Impact factor: 3.969

9.  Immunodeficiency in ataxia telangiectasia is correlated strongly with the presence of two null mutations in the ataxia telangiectasia mutated gene.

Authors:  E R Staples; E M McDermott; A Reiman; P J Byrd; S Ritchie; A M R Taylor; E G Davies
Journal:  Clin Exp Immunol       Date:  2008-05-26       Impact factor: 4.330

10.  Mortality and cancer incidence in 263 patients with ataxia-telangiectasia.

Authors:  D Morrell; E Cromartie; M Swift
Journal:  J Natl Cancer Inst       Date:  1986-07       Impact factor: 13.506

View more
  15 in total

Review 1.  Human genetic dissection of papillomavirus-driven diseases: new insight into their pathogenesis.

Authors:  Vivien Béziat
Journal:  Hum Genet       Date:  2020-05-20       Impact factor: 4.132

Review 2.  Immunodeficiencies Associated with Abnormal Newborn Screening for T Cell and B Cell Lymphopenia.

Authors:  Soma Jyonouchi; Artemio M Jongco; Jennifer Puck; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2017-03-28       Impact factor: 8.317

3.  Ataxia telangiectasia in Turkey: multisystem involvement of 91 patients.

Authors:  Hacer Akturk; Murat Sutcu; Ayper Somer; Sanem Piskin; Manolya Acar; Meral Ozmen; Umut Altinoglu; Burak Tatli; Nuran Salman
Journal:  World J Pediatr       Date:  2017-01-25       Impact factor: 2.764

4.  Ataxia-telangiectasia mutated is required for the development of protective immune memory after influenza A virus infection.

Authors:  Rachel Warren; William Domm; Min Yee; Andrew Campbell; Jane Malone; Terry Wright; Margot Mayer-Pröschel; Michael A O'Reilly
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-09-11       Impact factor: 5.464

5.  Neutrophil oxidative burst activates ATM to regulate cytokine production and apoptosis.

Authors:  C J Harbort; Paulo Vitor Soeiro-Pereira; Horst von Bernuth; Angela M Kaindl; Beatriz Tavares Costa-Carvalho; Antonio Condino-Neto; Janine Reichenbach; Joachim Roesler; Arturo Zychlinsky; Borko Amulic
Journal:  Blood       Date:  2015-10-21       Impact factor: 22.113

6.  FATC Domain Deletion Compromises ATM Protein Stability, Blocks Lymphocyte Development, and Promotes Lymphomagenesis.

Authors:  Maja Milanovic; Zhengping Shao; Verna M Estes; Xiaobin S Wang; Demis Menolfi; Xiaohui Lin; Brian J Lee; Jun Xu; Olivia M Cupo; Dong Wang; Shan Zha
Journal:  J Immunol       Date:  2021-02-03       Impact factor: 5.426

Review 7.  Ataxia telangiectasia: a review.

Authors:  Cynthia Rothblum-Oviatt; Jennifer Wright; Maureen A Lefton-Greif; Sharon A McGrath-Morrow; Thomas O Crawford; Howard M Lederman
Journal:  Orphanet J Rare Dis       Date:  2016-11-25       Impact factor: 4.123

8.  Altered mucosal immune response after acute lung injury in a murine model of Ataxia Telangiectasia.

Authors:  Olaf Eickmeier; Su Youn Kim; Eva Herrmann; Constanze Döring; Ruth Duecker; Sandra Voss; Sibylle Wehner; Christoph Hölscher; Julia Pietzner; Stefan Zielen; Ralf Schubert
Journal:  BMC Pulm Med       Date:  2014-05-29       Impact factor: 3.317

9.  Elevated IgM levels as a marker for a unique phenotype in patients with Ataxia telangiectasia.

Authors:  Alexander Krauthammer; Avishay Lahad; Lior Goldberg; Ifat Sarouk; Batia Weiss; Raz Somech; Michalle Soudack; Itai M Pessach
Journal:  BMC Pediatr       Date:  2018-06-04       Impact factor: 2.125

Review 10.  Inflammation, a significant player of Ataxia-Telangiectasia pathogenesis?

Authors:  Majid Zaki-Dizaji; Seyed Mohammad Akrami; Gholamreza Azizi; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  Inflamm Res       Date:  2018-03-26       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.